Back

Phenotypic functional activities of monocyte change during crosstalk with breast cancer cell and enhancing effect of metformin of IFN-γ-associated antitumor cytokine production.

Dahmani, Z.; Addou-Klouche, L.; Gizard, F.; Dahou, S.; Messaoud, A.; Chahinez Djebri, N.; Idris Benaissti, M.; Mostefaoui, M.; Terbeche, H.; Nouari, W.; Miliani, M.; Lefranc, G.; Fernandez, A.; Lamb, N. J.; Aribi, M.

2020-02-15 immunology
10.1101/2020.02.14.949412 bioRxiv
Show abstract

BackgroundImmune activities of monocytes (MOs) can be altered within the microenvironment of solid malignancies, including breast cancer. Metformin (1,1-dimethylbiguanide hydrochloride, MET), has been shown to decrease tumor cell proliferation, but its effects have yet to be explored with respect to the crosstalk between monocytes and breast cancer cells. Here, we investigated the effects of MET on overall phenotypic functional activities of autologous MOs during the interplay with primary breast cancer cells. MethodsHuman primary breast cancer cells were either cultured alone or co-cultured with autologous MOs before treatment with MET. ResultsMET downregulated both breast cancer cell proliferation and the ratio of phosphorylated Akt (p-Akt)-to-Akt in breast cancer cells. Additionally, we observed that, in the absence of MET treatment, the levels of LDH-based cytotoxicity, catalase, intracellular free calcium ions (ifCa2+), IL-10 and arginase activity were significantly reduced in co-cultures compared to those of MOs cultivated alone whereas levels of iNOS were significantly increased (for all comparisons, p < 0.05). In contrast, MET upregulated breast cancer cell LDH-based cytotoxicity levels when co-cultured with MO. MET also induced upregulation of both the inducible enzymatic activity of nitric oxide synthase (iNOS) and arginase activity in MO cells and co-culture systems, although these differences did not reach significant levels for iNOS activity (p > 0.05). MET greatly decreased phagocytic activity in isolated MOs while inducing a robust increase of catalase activity in co-culture systems and of superoxide dismutase (SOD) activity in MOs, but not in MOs co-cultured with breast cancer cells. MET strongly upregulated the levels of ifCa2+ in co-culture systems and IFN-{gamma} production in both isolated MOs and co-culture systems. Moreover, MET treatment markedly downregulated IL-10 production in MOs, while inducing a slight increase in co-cultures (p > 0.05). ConclusionsOur results show that the phenotypic functional activities of MOs change when co-cultured with primary human breast cancer cells. Furthermore, treatment with MET induced enhancing effects on the production of antitumor cytokine IFN-{gamma} and ifCa2+, as well as cytotoxicity during breast cancer cell-MO crosstalk. Novel Highlights includeO_LIFirst analysis of the anti-tumoral effects of Metformin on primary human breast cancer cells and the crosstalk with autologous monocytes. C_LIO_LIPhenotypic functional activities of monocytes change during their interplay with breast cancer cells, which is improved by upregulation of IFN-{gamma} after Metformin treatment. C_LIO_LIMetformin induces downregulation of phosphorylated-Akt1/2-to-Akt1/2 ratio in breast cancer cells. C_LIO_LIMetformin downregulates phagocytic capacity of monocyte from breast cancer patients. C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
586 papers in training set
Top 0.1%
36.5%
2
Cancers
200 papers in training set
Top 0.3%
10.7%
3
Breast Cancer Research
32 papers in training set
Top 0.1%
7.6%
50% of probability mass above
4
PLOS ONE
4510 papers in training set
Top 34%
4.2%
5
Scientific Reports
3102 papers in training set
Top 43%
2.8%
6
Cell Communication and Signaling
35 papers in training set
Top 0.3%
2.0%
7
Frontiers in Oncology
95 papers in training set
Top 2%
1.8%
8
Immunology
29 papers in training set
Top 0.5%
1.4%
9
Cells
232 papers in training set
Top 3%
1.4%
10
Frontiers in Physiology
93 papers in training set
Top 3%
1.4%
11
Biomedicines
66 papers in training set
Top 2%
1.0%
12
International Journal of Molecular Sciences
453 papers in training set
Top 12%
0.9%
13
Integrative Biology
13 papers in training set
Top 0.1%
0.9%
14
OncoImmunology
22 papers in training set
Top 0.3%
0.9%
15
eBioMedicine
130 papers in training set
Top 3%
0.9%
16
iScience
1063 papers in training set
Top 29%
0.8%
17
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
18
Clinical and Translational Science
21 papers in training set
Top 1%
0.7%
19
European Journal of Immunology
57 papers in training set
Top 0.6%
0.7%
20
BMC Cancer
52 papers in training set
Top 3%
0.5%
21
Brain, Behavior, & Immunity - Health
27 papers in training set
Top 0.7%
0.5%
22
Aging
69 papers in training set
Top 4%
0.5%
23
Vaccines
196 papers in training set
Top 3%
0.5%
24
FEBS Open Bio
29 papers in training set
Top 0.8%
0.5%
25
BMC Medicine
163 papers in training set
Top 8%
0.5%
26
Molecular Immunology
14 papers in training set
Top 0.6%
0.5%
27
Cytotherapy
14 papers in training set
Top 0.4%
0.5%